Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Public ClinicalTrials.gov record NCT03432741. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET
Study identification
- NCT ID
- NCT03432741
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 17 participants
Conditions and interventions
Conditions
- Breast Adenocarcinoma
- Metastatic Breast Carcinoma
- Recurrent Breast Carcinoma
- Recurrent Hodgkin Lymphoma
- Recurrent Mycosis Fungoides
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Refractory Breast Carcinoma
- Refractory Hodgkin Lymphoma
- Refractory Mycosis Fungoides
- Refractory Nodal Marginal Zone Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Stage IV Breast Cancer AJCC v6 and v7
Interventions
- Belinostat Drug
- Carfilzomib Drug
- Copanlisib Hydrochloride Drug
- Daratumumab Biological
- Fludeoxyglucose F-18 Drug
- Gemcitabine Hydrochloride Drug
- Laboratory Biomarker Analysis Other
- Nivolumab Biological
- Obinutuzumab Biological
- Pembrolizumab Biological
- Positron Emission Tomography Procedure
- Rituximab Biological
- Romidepsin Drug
- Saline Other
- Trastuzumab Biological
Drug · Biological · Other + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 26, 2018
- Primary completion
- Aug 25, 2022
- Completion
- Oct 2, 2022
- Last update posted
- May 25, 2025
2018 – 2022
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03432741, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 25, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03432741 live on ClinicalTrials.gov.